

# Introduction to clinical epidemiology and research methodology

Chaiyawat Suppasilp, M.D.

Department of Clinical Epidemiology and Biostatistics

Faculty of Medicine Ramathibodi Hospital Mahidol University

August 2021

# Content

- Introduction to Clinical Epidemiology
- Steps of Doing Research
- Measurements in Epidemiology
- Study design
- Evidence-based Medicine

# Introduction to Clinical Epidemiology

- Definitions
- The purpose of Clinical Epidemiology
- Basic principles

# Definition

Clinical Epidemiology = Clinical medicine + Epidemiology

## **Epidemiology**

Epidemiology is the study (scientific, systematic, and data-driven) of the distribution (frequency, pattern) and determinants (causes, risk factors) of health-related states and events (not just diseases) in specified populations (neighborhood, school, city, state, country, global).

It is also the application of this study to the control of health problems

(Last JM, editor. Dictionary of epidemiology. 4th ed. New York: Oxford University Press; 2001. p. 61.)


The health sciences and their complementary relationships.

# Definition

## Clinical Epidemiology

Clinical epidemiology is the science of making predictions about individual patients by counting clinical events (the 5 Ds) in groups of similar patients and using strong scientific methods to ensure that the predictions are accurate.

Clinical Epidemiology is the application of epidemiological methods to the care of individual patients (to the practice of clinical medicine).



Clinical epidemiology 5ed, Robert H Fletcher

# Definition


## Evidence-based Medicine

“Expertise in integrating

1. Best research evidence
2. Clinical Circumstance
3. Patient values

in clinical decisions”

(Haynes, Devereaux, & Guyatt, 2002)



# The purpose of Clinical Epidemiology

To foster methods of clinical observation and interpretation that lead to valid conclusions and better patient care.

Basic principles:

- Observations should address questions facing patients and clinicians
- Results should include patient-centered health outcomes (the 5 Ds)
- Etc.

# Basic principles: Outcome of Disease

| Outcomes of Disease (the 5 Ds) |  |
|--------------------------------|--|
| <b>Death</b>                   | A bad outcome if untimely  |
| <b>Disease</b>                 | A set of symptoms, physical signs and laboratory abnormalities<br>( the patient's experience of disease) |
| <b>Discomfort</b>              | Symptoms such as pain, nausea, dyspnea, itching, and tinnitus  |
| <b>Disability</b>              | Impaired ability to go about usual activities at home, work, or recreation                               |
| <b>Dissatisfaction</b>         | Emotional reaction to disease  |
| <b>Destitution</b>             | The financial cost of illness (for individual patients or society)                                       |

Clinical epidemiology 5ed, Robert H Fletcher



# Basic principles: Variables


## Variables

Attributes of patients and clinical event that vary and can be measured

## Types of variables

- Independent variable: Predictor, purported cause
- Dependent variable: Outcome, possible effect
- Extraneous variable: Covariates, may affect the relationship between independent and dependent variable

# Basic principles: Population & Sample



# Basic principles: Error


The difference between the retained value and the true value.

## Types of error

- Random error (by Chance)
- Systematic error (Bias)

A Process at any stages of inference  
(Design, Conduct, Analysis, Interpretation, and Conclusion)  
tending to produce results that depart systematically from true values.

# Basic principles: Error



# Bias (Systematic error)

| Bias in Clinical Observation |   |
|------------------------------|---|
| Selection bias               | Occurs when comparisons are made between groups of patients that differ in determinates of outcome other than the one under study.      |
| Measurement bias             | Occurs when the methods of measurement are dissimilar among groups of patients  |
| Confounding                  | Occurs when two factors are associated (travel together) and the effect of one is confused with or distorted by the effect of the other |

# Selection Bias


A nonrandom selection of study participants leads to erroneous conclusions or method or conduct to absence of comparability between groups being studied.

## **Common selection biases**

- Berkson Bias (Hospital case differ than community population)
- Unmasking bias/Ascertainment bias/Surveillance bias
- Healthy worker effect (EGAT Good vs Poor)
- Volunteer Bias (Healthy or diseases sample e.g. MRI brain)
- Non-Response Bias (e.g. Questionnaire sexual issue, confidential issue)

# Example 1: Berkson bias

It can arise when the sample is taken not from the general population, but from a subpopulation.



In hospital: OR = 4.06

In community: OR = 1.06

# Measurement Bias

- Occurs when the method of measurement leads to systematically incorrect results
- Incorrect determination of exposure or outcome, or both
- Gathering information in different way


## **Common measurement biases**

- Recall bias
- Observer bias
- Attention bias (Hawthorn effect)
- Insensitive measurement bias
- Lead time bias
- Response bias



# Example 2: Lead-time bias


Lead time bias refers to the phenomenon where early diagnosis of a disease falsely makes it look like people are surviving longer. This occurs most frequently in the context of screening.



# Confounding (Bias)

A confounding variable is associated with the exposure and it affects outcome, but it is **not** in an intermediate link in the chain of causation between exposure and outcome

- A **priority criteria of confounder**



# Example 3: Confounding

Cohort study of Hot tea drinking and Gastric cancer

|       | Tea + | Tea - |     |
|-------|-------|-------|-----|
| CA    | 27    | 14    | 41  |
| No CA | 48    | 67    | 115 |
| Total | 75    | 81    | 156 |

Relative Risk = 2.1

Non-Smoker

|            | Tea + | Tea - |    |
|------------|-------|-------|----|
| CA Stomach | 1     | 2     | 3  |
| No CA      | 24    | 48    | 72 |
| Total      | 25    | 50    | 75 |

Relative Risk = 1 No association

Smoker

|            | Tea+ | Tea - |    |
|------------|------|-------|----|
| CA Stomach | 26   | 12    | 38 |
| No CA      | 24   | 19    | 43 |
| Total      | 50   | 31    | 81 |

Relative Risk = 1.23 Confounder

# Confounding (Bias)


Control and minimized of confounder

## Design Phase

- Exclusion (Restriction)
- Matching
- Randomization and blind assessed

## Analysis Phase

- Adjustment (standardized)
- Stratification
- Multivariate Analysis



# Random error (Chance)

A portion of variation in a measurement that has no apparent connection to any other measurement or variable, generally regarded as due to chance.

- Type I Error (Alpha): Rejecting the null hypothesis when it is true (False Positive)
- Type II Error (Beta): Accepting the null hypothesis when it is false (False Negative)

$$H_0: u_{SBP(A)} = u_{SBP(B)}$$
$$H_1: u_{SBP(A)} \neq u_{SBP(B)}$$

| Statistical Testing                        | In Population<br>Different exist (+)         | No Different exist (-)                        |
|--|--|---|
| Different (+)<br>Reject Null Hypothesis    | Power<br>1-Beta                              | False Positive (alpha)<br><b>Type I Error</b> |
| No-Different (-)<br>Accept Null Hypothesis | False Negative(Beta)<br><b>Type II Error</b> | True Negative<br>1-alpha                      |

# Random error (Chance)

## Sources of error

- Small sample size
- High variation in Samples/Subjects
- Measurement-influenced errors
  - One-time measurement (or too many measurement)
  - Non-standardized measurement
  - Unreliable measurement (no calibration)

# Random error (Chance)

## How to assess random error

### P-value

A numeric representative of the degree to which random variation alone could account for the difference observed between groups or data being compared  
e.g.  $P < 0.05$ ,  $P < 0.01$

### Confidence interval

Provide a plausible range within which the true association lies and provide all the information in P-value and more.

# Random error (Chance)


## **Strategies to reduce random error**

- Appropriated sample size (Not largest sample size)
- Precise measurement endpoint
- Standardizing aspect of the protocol which impact on patient to patient variations
- Collecting data on key prognostic factors
- Choosing a homogenous group of patient
- Choosing the most appropriated design



# Basic principles: Internal & External validity

- **Internal validity** is the degree to which the results of a study are correct for the sample of patients being studied.
- **External validity** (generalizability) is the degree to which the results of an observation hold true in other settings.



# Steps of Doing Research

# Steps of Doing Research

1. Research questions
2. Reviews and literature searching
3. Create study design:
  - Methodology, Sample size, Measurement etc.
  - Protocol wringing, Ethic submission
4. Perform Data correction
  - Select database program: Epidata, Excel, SQL
  - Design database and variables
5. Data management (entry, validation)
6. Statistical analysis
7. Results/ Conclusion (+/- publication)

# Research question

- Good research question:
  - Relevant
  - Interesting
  - Focused
- Component of Research question
  - **P**opulation (Patients, Problems)
  - **I**ntervention (exposure)
  - **C**ontrol (comparison)
  - **O**utcome

# Clinical scenario 1

- A 67-year-old woman was found to have HT 12 years ago.
- Her blood pressure is uncontrolled in last year of follow-up even 4 anti-hypertensive agents were prescribed.
- Her serum creatinine is 1.6 mg/dl (eGFR 33 cc/min/1.73m<sup>2</sup>).
- You wonder this patient may have renal artery stenosis and ischemic nephropathy.
- You ask your advisor and he suggested to perform MRA.
- But you think about CTA.

# Research question 1

What is the accuracy of MRA compared with CTA in diagnosed of renal artery stenosis among uncontrolled hypertension population?

# PICO

**Patient**

**Intervention or Exposure**

**Comparison**

**Outcome**


# Measurements in Epidemiology



# Measurement in Epidemiology

- Measures of disease frequency
- Measures of association
- Measures of potential impact

# Measurement in Epidemiology



# Measures of disease frequency

Measures of disease frequency in mathematical quantity

- Count
- Fraction
  - Rate
  - Ratio
  - Proportion (percentage)

Measures of disease frequency in epidemiology

- Prevalence
- Incidence

# Count

- Simplest & most basic measure –absolute number of persons who have disease or characteristic of interest.
- Useful for health planners & administrators: for allocation of resources (e.g. quantity of ORS needed by diarrheal cases)

## **Limitations**

- It depends on the size of the population at risk of the disease in an area. (e.g. the bigger group, the higher is the expected number of cases)
- The duration of observation also affects the frequency of cases. (e.g. the longer the observation period, the more cases can occur.)

# Incidence and Prevalence

**Incidence(I):** Measures **new cases** of a disease that develop over a period of time.

- Cumulative incidence = incidence proportion (incidence)
- Incidence rate = incidence density rate (hazard rate)

**Prevalence(P):** Measures **existing cases** of a disease at a particular point in time or over a period of time.

- Point prevalence
- Period prevalence

# Incidence proportion

Number of new cases of disease or injury during specified period

---

Size of population at start of period

In 2001, among 5,572 women aged 20-39 years who were sex workers, there were 45 HIV positive cases during 2002-2005


SO, The cumulative incidence of HIV positive cases during these 4 years

=

# Incidence rate

|  |
|--|
| Number of new cases of disease or injury during specified period |
| Time each person was observed, totaled for all persons           |

Hypothetical cohort of 12 initially disease-free subjects followed over a 5-year period from 1990 to 1995.



$$\hat{IR} = \frac{I}{PT} = \frac{5}{25 \text{ PY}} = 0.20$$

x: disease      O: death

# Prevalence

All new and pre-existing cases during a given time period

---

Population during the same time period

In a survey of 1,150 women who gave birth in Ramathibodi hospital in 2000, a total of 468 reported taking a multivitamin at least 4 times a week during the month before becoming pregnant.


The prevalence of frequent multivitamin use in this group

=



# Prevalence and Incidence

- Incidence measure appearance of the disease  
Prevalence measure the existing of the disease
- Incidence means NEW  
Prevalence means ALL
- $\text{Prevalence} = \text{Incidence} \times \text{duration}$   
(the relationship is most apparent in a stable, chronic disease)
- Prevalence is based on both incidence and duration of illness. High prevalence of a disease within a population might reflect high incidence or prolonged survival without cure or both. Conversely, low prevalence might indicate low incidence, a rapidly fatal process, or rapid recovery.




# Example:

- From total of 1000 cases, there are 20 and 10 new cancer cases detected in the first and second year, respectively.
- Find the cumulative incidence of the first years
- Find the cumulative incidence of the second years
- Find the cumulative incidence of these two years

# Measures of association

- Absolute Difference
  - Risk Difference or Excess Risk or Absolute Risk Reduction or Attributable Risk
  - Number needed to treat (NNT)
  - Number needed to harm (NNH)
- Relative Difference (Ratio measurement or Relative risk)
  - Risk Ratio (Relative Risk)
  - Odds Ratio (Relative Odds)

# Risk vs Odds



$$\text{Odds} = \frac{P(\text{event})}{1 - P(\text{event})}$$

$$\text{Risk} = \frac{\text{number of cases of disease}}{\text{number of people at risk}}$$

$$\text{Risk}(\text{Red}) =$$

$$\text{Risk}(\text{Green}) =$$

$$\text{Odds} = \frac{\text{Chance that event occurs}}{\text{Chance that event dose not occur}}$$

$$\text{Odds}(\text{Red}) =$$

$$\text{Odds}(\text{Green}) =$$

# Risk ratio (RR) vs Odds Ratio (OR)

$$\text{Risk Ratio} = \frac{\text{Risk of disease in Exposed, Treatment Group}}{\text{Risk of disease in Non - exposed, Control Group}}$$

$$\text{Odds Ratio} = \frac{\text{Odds of disease in Exposed, Treatment Group}}{\text{Odds of disease in Non - exposed, Control Group}}$$

# Example

|                    | <b>Disease</b> | <b>No Disease</b> | <b>Total</b> |
|--------------------|----------------|-------------------|--------------|
| <b>Smoking</b>     | 100            | 1,900             | 2,000        |
| <b>Non-smoking</b> | 80             | 7,920             | 8,000        |
| <b>Total</b>       | 180            | 9,820             | 10,000       |

- Risk of having the disease in Exposed Group =
- Risk of having the disease in Non-exposed Group =
- Risk Ratio (Relative Risk) =
- Meaning:
  - = The risk of developing the disease in smoking group is 5 times of non-smoking group
  - = The risk of developing the disease in smoking group is 4 times higher than non-smoking group

# Example

|             | Disease | No Disease | Total  |
|-------------|---------|------------|--------|
| Smoking     | 100     | 1,900      | 2,000  |
| Non-smoking | 80      | 7,920      | 8,000  |
| Total       | 180     | 9,820      | 10,000 |

- Odds of having the disease in Exposed Group =
- Odds of having the disease in Non-exposed Group =
- Odds Ratio (Relative Odds) =
- Meaning:
  - = The odds of developing the disease in smoking group is 5.2 times of non-smoking group
  - = The odds of developing the disease in smoking group is 4.2 times higher than non-smoking group

# OR vs RR

- If the interested event is rare (or very rare), OR and RR are similar.




Figure 3.1. The odds ratio against the relative risk. The fanned lines are each drawn at a specific value (as so labelled) of the risk of disease in subjects who are unexposed to the risk factor. The diagonal solid line is the line of equality between the odds ratio and the relative risk.



# Why we use Odds??


- Multiple logistic regression, a frequently used multivariate technique, calculates adjusted ORs and not RRs.
- The odds ratio would be substantially larger than the relative risk.
- Meta-analysis: each study has their own prevalence, using Odds is better.
- In retrospective (case-control) studies, where the total number of exposed people is not available, RR cannot be calculated, and OR is used as a measure of the strength of association between exposure and outcome.
- By contrast, in prospective studies (cohort studies), where the number at risk (number exposed) is available, either RR or OR can be calculated.

# Measure of potential impact

- Reflects the burden that an exposure contribute to the frequency of disease in the population
- Impact of exposure removal
- Two concepts
  - Attributable risk among exposed
  - Population attributable risk

# Attributable Risk (AR)


- Quantifies disease burden in exposed group attributable to exposure.
- Provides answer to
  - What is the risk which can be attributed to the exposure?
  - What is the excess risk due to the exposure?
- Calculated as risk difference (RD)



*I = Incidence*

# Population Attributable Risk (PAR)

- Excess risk of disease in total population attributable to exposure.
- Reduction in risk which would be achieved if population entirely unexposed.
- Helps determining which exposures relevant to public health in community.
- $PAR = AR * \text{Prevalence of exposure in the population}$



# Attributable Risk fraction

- Attributable risk in the exposed group

$$AR\% = \frac{I_{\text{exposed}} - I_{\text{unexposed}}}{I_{\text{exposed}}}$$

- Attributable risk in the total population

$$PAR\% = \frac{I_{\text{population}} - I_{\text{unexposed}}}{I_{\text{population}}}$$

# Example

- Consider a cohort study of risk of ischemic stroke, taken in 1 year, with 500 subjects with atrial fibrillation (AF) controlled against 500 subjects without AF.
- Given the proportion of AF in general population is 30%.
- The results are summarized as follow:

|              | <b>Ischemic<br/>stroke: present</b> | <b>Ischemic<br/>stroke: absent</b> | <b>Total</b> |
|--------------|-------------------------------------|------------------------------------|--------------|
| <b>AF</b>    | 2                                   | 498                                | 500          |
| <b>No AF</b> | 1                                   | 499                                | 500          |
| <b>Total</b> | 3                                   | 997                                | 1000         |

# Study design

# Types

## **By study design**

- Experimental, Observational study
- Descriptive, Analytic study

## **By category of clinical question**

- Risk
- Prognosis
- Therapy
- Diagnosis



# Classification of study design


## **Observational study**

- Descriptive or case series
- Cross-sectional study
- Case control studies(retrospective)
- Cohort studies(prospective)
- Historical cohort studies (retrospective)


## **Experimental study**

- Controlled trials
- Studies with no controls

## **Systematic Reviews/Meta analysis**




# Hierarchy of evidences



# Cross-Sectional study

- Study about the characteristics of a population at one point in time (like a photo “snapshot”) (also for a short period of time)
- No intervention
- Usually a prevalence study (Not incidence study)
- Hardly to control bias
- Can establish **association** but NOT “causation”




# Cross-Sectional study

| Advantages               | Disadvantages   |
|--------------------------|---|
| Simple (no follow-up)    | Can establish <b>association</b> <u>but NOT “causation”</u>   |
| Inexpensive              | Hardly to control bias: <ul style="list-style-type: none"><li>• Confounding</li><li>• Recall bias</li><li>• Incidence-prevalence bias</li></ul> |
| No drop out              |   |
| No intervention/exposure |   |

# Case-Control study

- Study Subjects Participants selected based on outcome status
  - Case-subjects have outcome of interest
  - Control-subjects do not have outcome of interest



# Case-Control study

- Study Subjects Participants selected based on outcome status
  - Case-subjects have outcome of interest
  - Control-subjects do not have outcome of interest
- Usually Retrospective study
- Used for studying rare diseases
- For multiple exposures that may be related to a single outcome
- Use Odds ratio (OR) Not Relative risk (RR)  
(in rare disease, it is ok to use RR, will be discuss later)


# Case-Control study

| Advantages                                   | Disadvantages                               |
|--|---|
| Quickly and inexpensive                      | Recall Bias                                 |
| Feasible for rare disorder or long follow-up | More effect of confounder                   |
| May required fewer subjects                  | Difficult to find control group             |
|  | OR is not easy to understand by physicians. |



# Cohort Study

- Participants classified according to exposure status and followed-up over time to ascertain outcome.
- Ensures temporality (exposure occurs before observed outcome)




# Cohort Study

## Types of cohort study

### Historical cohort studies (retrospective)

### Cohort studies (prospective)




# Cohort Study

| Advantages  | Disadvantages                              |
|---|--|
| Can be matched  | Relatively expensive                       |
| Can establish temporal association                            | Hard to blind                              |
| Can be standardized in eligible criteria & outcome assessment | Long follow-up period for rare disorder    |
|   | Difficult to find controls and confounders |
|   | Follow-up need manpower                    |

# Randomized Controlled Trial (RCT)

- Give intervention/ exposure/ treatment to participants




# Randomized Controlled Trial (RCT)

| Advantages   | Disadvantages                                 |
|--|---|
| Confounding and variables can be balance by randomization  | High cost in term of time and money           |
| Blinding of subjects, medical staff and investigators are achievable (Selection bias is minimized, but volunteer bias is <u>not</u> minimized) | Dropout or loss to follow up are common event |
| Considered to be the best sort of experimental study   | Need time to final results                    |

# Why do not always perform RCT?

## Hierarchy of evidences



# Example 01

- A study has been conducted to assess an effect of alcohol consumption on the risk of liver cancer using data registry of health of workers of one company between 2000-2010.
- Alcohol consumption was collected at baseline and follow up until the occurrences of liver cancer documented in medical records.
- What is an appropriate study design?
  - A cross-sectional study
  - A prospective cohort study
  - A retrospective cohort study
  - A case-control study
  - A clinical trial



# Example 02

- 120 women with endometrial cancer and another 480 women with no apparent disease were contacted and asked whether they had ever used estrogen. Each woman with cancer was matched by age, race, weight, and parity to a woman without disease.
- What is an appropriate study design?
  - A cross-sectional study
  - A prospective cohort study
  - A retrospective cohort study
  - A case-control study
  - A clinical trial



# OR vs RR

- In retrospective (case-control) studies, where the total number of exposed people is not available, RR cannot be calculated, and OR is used as a measure of the strength of association between exposure and outcome.
- By contrast, in prospective studies (cohort studies), where the number at risk (number exposed) is available, either RR or OR can be calculated.



# Clinical question and Study design

- Diagnosis Demonstrate that new diagnosis test is valid/reliable, preferred “cross sectional study”
- Causation or Risk Determine that agent is related to development of illness, preferred “Cohort or case-control study”
- Therapy Testing the efficacy of intervention preferred “RCT”
- Prognosis determine what happen to someone with some stage of disease, preferred “Prospective Cohort study”

# Evidence-based Medicine


# Evidence-based Medicine

“Expertise in integrating

1. Best research evidence
2. Clinical Circumstance
3. Patient values

in clinical decisions”

(Haynes, Devereaux, & Guyatt, 2002)



# How do we actually practice EBM?

## 5 A's of EBM


Step 1: Ask answerable question

Step 2: Find Articles

Step 3: Critical Appraisal the evidence

Step 4: Apply

Step 5: Assess patient preference



# Critical appraisal

Board issues need to be considered.

- Are the results of the study valid?
- What are the results?
- How can you apply the results to patient care?

# Critical appraisal: Tools

## CEBM


(The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare.)

### mnemonics

Question: PICO

Method: RAMMbo

- Recruitment
- Allocation
- Maintenance
- Measurements



[www.cebm.net](http://www.cebm.net)

|             |                       |           |                |
|-------------|-----------------------|-----------|----------------|
| Author:     |                       | Ref:      |                |
| Description |                       | Numbers   |                |
| Question    | <b>P</b> atients      |           |                |
|             | <b>I</b> ntervention  |           |                |
|             | <b>C</b> omparator    |           |                |
|             | <b>O</b> utcomes      |           | <b>CER (%)</b> |
| 1           |                       |           |                |
|             | 2                     |           |                |
| Appraisal   | <b>R</b> andomized    |           |                |
|             | <b>A</b> scertainment |           |                |
|             | <b>M</b> easures      |           |                |
| Outcomes    | <b>R</b> Difference   | CER – EER |                |
|             | <b>R</b> RR           | RD/CER    |                |
|             | <b>N</b> NT           | 1/RD      |                |

Clinical Bottom-line:

Further Actions:

# Appraisal checklist -RAMMbo

## Was the Study valid?

**Recruitment:** Who did the subjects represent?

**Allocation:** Was the assignment to treatments randomized?  
Were the groups similar at the trial's start?

**Maintenance:** Were the groups treated equally?  
Were outcomes ascertained & analyzed for most patients?

**Measurements:** Were patients and clinicians "blinded" to treatment? OR  
Were measurements objective & standardized?

Study statistics (p-values & confidence intervals)



# Critical appraisal: Tools




**How to use this appraisal tool:** Three broad issues need to be considered when appraising a trial:

- └ Are the results of the study valid? (Section A)
- └ What are the results? (Section B)
- └ Will the results help locally? (Section C)

<https://casp-uk.net/casp-tools-checklists/>

# EBM is lifelong learning process






*Dr. Gordon Guyatt*

# Acknowledgement

- Prof.Ammarin Thakkinstian, Ph.D.
- Assoc.Prof. Atiporn Ingsathit, M.D., Ph.D.
- Asst.Prof. Pawin Numthavaj, M.D., Ph.D.
- Aj. Chusak Okascharoen, MD, PhD
- Aj. Kunlawat Thadanipon, M.D., Ph.D.

# References



**Thank you**

Chaiyawat Suppasilp